IAVI and Lentigen to Collaborate on Design of Novel AIDS Vaccine Candidate

IAVI and biotechnology company, Lentigen Corporation, announced a collaboration to design a preventive AIDS vaccine based on Lentigen's technology. The candidate AIDS vaccine will be devised to safely mimic biological aspects of HIV infection and will be tested first in pre-clinical studies as part of an initial 18-month agreement. The use of Lentigen's technology could allow researchers to come remarkably close to the live-attenuated strategy of HIV vaccine development.  The announcement is below.

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account